期刊
BLOOD
卷 126, 期 11, 页码 E19-E29出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2015-02-624551
关键词
-
类别
资金
- Amgen
- ZOLL Lifecor
- Johnson Johnson
- Nestle Nutrition (Nestec Ltd.)
- Metagenics Inc.
- AXA
- BBSRC [BB/F019394/1] Funding Source: UKRI
- MRC [MC_PC_U127561128, G0700704] Funding Source: UKRI
- Biotechnology and Biological Sciences Research Council [BB/F019394/1] Funding Source: researchfish
- Chief Scientist Office [CZB/4/505, ETM/55] Funding Source: researchfish
- Medical Research Council [MR/K026992/1, MC_PC_U127561128, G0700704] Funding Source: researchfish
Fibrinogen, coagulation factor VII (FVII), and factor VIII (FVIII) and its carrier von Willebrand factor (vWF) play key roles in hemostasis. Previously identified common variants explain only a small fraction of the trait heritabilities, and additional variations may be explained by associations with rarer variants with larger effects. The aim of this study was to identify low-frequency (minor allele frequency [MAF] >= 0.01 and < 0.05) and rare (MAF < 0.01) variants that influence plasma concentrations of these 4 hemostatic factors by meta-analyzing exome chip data from up to 76 000 participants of 4 ancestries. We identified 12 novel associations of low-frequency (n=2) andrare (n=10) variants across the fibrinogen, FVII, FVIII, and vWF traits that were independent of previously identified associations. Novel loci were found within previously reported genes and had effect sizes much larger than and independent of previously identified common variants. In addition, associations at KCNT1, HID1, and KATNB1 identified new candidate genes related to hemostasis for follow-up replication and functional genomic analysis. Newly identified low-frequency and rare-variant associations accounted for modest amounts of trait variance and therefore are unlikely to increase predicted trait heritability but provide new information for understanding individual variation in hemostasis pathways.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据